Impact Analysis of Covid-19
The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
Anti-inflammatory drugs are the class of analgesics, which are used to treat multisystem inflammatory disorders. These drugs are used to relieve pain, reduce inflammation, or treat fever. These drugs are used worldwide on prescriptions as well as off label in tablets, capsules, creams, liquids, injections, sprays, and suppositories. Moreover, increasing incidence of acute and chronic diseases are expected to boost the market growth. For instance, according to an article published by the National Kidney Foundation Inc. in November 2019, reports that the prevalence of gout in the U.S. has been doubled since 1990s and now estimated that 3.9% i.e. 8.3 million adults in the U.S. had gout, amongst which 6.1 million were men and 2.2 million were women.
The global anti-inflammatory drugs market is estimated to be valued at US$ 79,830.2 million in 2020 and is expected to exhibit a CAGR of 8.6% during the forecast period (2020-2027).
Figure 1. Global Anti-inflammatory Drugs Market Share (%), by Region, 2020
Ongoing research and development for the anti-inflammatory drugs is expected to propel growth of the global anti-inflammatory drugs market
Continuous research and development followed by approvals and launches of the anti-inflammatory drugs are expected to boost the market growth over the forecast period. For instance, in April 2020, InDex Pharmaceuticals Holding AB, received positive responses from the U.S. Food and Drug Administration (U.S. FDA) and European Medicines Agency (EMA) about the phase III trial of TLR9 agonist cobitolimod. This drug is a potential new medication for patients with active moderate to severe ulcerative colitis, a chronic inflammatory bowel disease.
However, failure of drug results in the clinical trial is expected to hinder the market growth over the forecast period. For instance, in July 2020, F. Hoffmann-La Roche AG, multinational healthcare company announced that its COVACTA trial of Actemra (tocilizumab), anti-inflammatory drug failed to meet its primary endpoint of improvement. The drug was supposed to support the patients who were hospitalized with severe COVID-19 pneumonia but failed as it proved ineffective and failed to improve outcomes in the disease.
Anti-inflammatory Drugs Market Report Coverage
||Market Size in 2020:
||US$ 79,830.2 Mn
|Historical Data for:
||2016 to 2019
||2020 to 2027
|Forecast Period 2020 to 2027 CAGR:
||2027 Value Projection:
||US$ 142,223.4 Mn
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
- By Drug Type: Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Immune Selective Anti-inflammatory Derivatives (ImSAIDs), Anti-inflammatory Biologics, Corticosteroids.
- By Application: Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Gout, Others.
- By Route of Administration: Oral, Topical, Injection, Inhalation.
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Company, Inc., Novartis AG, Amgen, Inc., AstraZeneca plc, Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Biogen Inc., Sun Pharmaceutical Industries Ltd, Mylan, Inc., Aurobindo Pharma Limited, and Dr. Reddy’s Laboratories.
- Rising incidence of acute and chronic diseases
- Product development and ongoing trials for anti-inflammatory drugs
|Restraints & Challenges:
- Side-effects of anti-inflammatory drugs
- Drug failures
Figure 2. Global Anti-inflammatory Drugs Market Share (%), by Drug Type, 2020
Increasing cases of acute and chronic diseases in North America is expected to boost the market growth
North America is expected to hold dominant position in the global anti-inflammatory drugs market, owing to increasing new cases of acute and chronic diseases in this region. For instance, according to an article published by the Arthritis Foundation in 2017, reports that the number of adults in the U.S. with doctor-diagnosed arthritis is estimated to increase by 49% to reach 78.4 million (25.9% of all adults) by 2040.
Global Anti-inflammatory Drugs Market – Impact of Coronavirus (COVID-19) Pandemic
The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses in all sectors. The private healthcare is one such sector which has been impacted significantly by the COVID-19 pandemic.
The lockdown in various countries due to the pandemic has placed an economic burden on the healthcare sector. Moreover, the coronavirus pandemic has hampered the development, production, and supply of drugs and other healthcare products and affected growth of healthcare businesses of various companies across the globe.
As a result, the impact of the COVID-19 pandemic is also expected to limit growth of the global anti-inflammatory drugs market during the forecast period.
Major players operating in the global anti-inflammatory drugs market include Pfizer, Inc., GlaxoSmithKline plc, Johnson & Johnson Services Inc., Merck & Company, Inc., Novartis AG, Amgen, Inc., AstraZeneca plc, Eli Lily and Company, AbbVie Inc., F. Hoffmann-La Roche AG, Bristol Myers Squibb Company, Biogen Inc., Sun Pharmaceutical Industries Ltd, Mylan, Inc., Aurobindo Pharma Limited, and Dr. Reddy’s Laboratories among others.